<DOC>
	<DOC>NCT03018067</DOC>
	<brief_summary>This phase 2, single-blind, placebo-controlled study will evaluate the onset-of-action, safety, and efficacy of RDX227675 for the treatment of hyperkalemia. Subjects who qualify are randomized into one of four treatment groups: Group 1 (Placebo qd), Group 2 (RDX227675 10 g qd), Group 3 (RDX227675 20 g qd), Group 4 (RDX227675 30 g qd).</brief_summary>
	<brief_title>A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia</brief_title>
	<detailed_description>The study consists of a screening visit, a 7-day treatment period, and a 7-day treatment-free follow-up period.</detailed_description>
	<mesh_term>Hyperkalemia</mesh_term>
	<criteria>18 to 85 years old, inclusive Two consecutive iSTAT K values ≥ 5.5 to &lt; 6.5 mmol/L, measured a minimum of 60minutes apart within 1 day of first RDX227675 dose on Day 1 (prior to randomization) iSTAT K value ≥ 5.5 to &lt; 6.5 mmol/L on Day 1 (prior to randomization) Ability to have repeated blood draws or effective venous catheterization Females of child bearing potential must have negative urine pregnancy test on Day 1 (prior to randomization) Females but be nonpregnant, nonlactating, and either be postmenopausal for at least 12 months, have documentation of irreversible surgical sterilization, or confirm the use of one of the acceptable contraceptive methods Males must agree to use an appropriate method of contraception or have documented surgical sterilization Pseudohyperkalemia signs and symptoms Treatment with K lowering drugs, within 7 days prior to randomization Uncontrolled Type 2 diabetes, as defined as most recent historical HbA1c &gt; 10%, or hospitalization to treat hyper or hypoglycemia in the past 3 months Diabetic ketoacidosis Known hypersensitivity to polystyrene sulfonate Significant cardiovascular or cerebrovascular events in the past 2 months Severe heart failure, defined as NYHA (New York Heart Association) class IV or hospitalization to treat heart failure in previous 3 months History of bowel obstruction, swallowing disorders, severe gastrointestinal disorders, or major gastrointestinal surgery Major psychiatric disorder (DSMIIIR or DSMIV) including major depression or other psychoses that has required hospitalization in the last 3 years. History of attempted suicide or uncontrolled bipolar disorder. Use of an investigational product within 30 days prior to Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>